Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 21:01:26 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Scandion Oncology Q4 2022 - Some stability has returned

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Scandion Oncology Q4 2022 - Some stability has returned

2023-02-22 13:22:00

Redeye comments on Scandion Oncology’s Q4 2022 report, with a new CEO in place and two study readouts in 2023e. However, we believe that the most important trigger for Scandion’s share constitutes CORIST part 4 efficacy data in H1 2024e. Given a challenging funding environment for Biotech companies, we judge that positive clinical results in 2023e-2024e will be critical to enable future capital raises.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/